Use of ZNF268 gene splicing isomer in treating leukaemia

The invention discloses an application of a ZNF268 gene splice variant in anti-leukemia, which aims at providing the application of one splice variant of the human zinc finger protein ZNF268 gene in preparing medicaments for curing or preventing leukemia. The splice variant of the human ZNF268 gene is named ZNF268a and is an expression product after that an mRNA precursor produced by transcribing the ZNF268 gene is spliced selectively to delete the integrated number six exon. The splice variant has the expression form with particularity in blood cells of leukemia patients, therefore, the expression marks can be detected by the RT-PCR method and can be used for clinical diagnosis of the leukemia. The application of the ZNF268 gene splice variant in preparing the medicaments for curing or preventing leukemia can quickly and correctly judge whether the leukemia happens.